Gastric Cancer Foundation Invites Researchers to Apply for Grants to Support Early-Stage Projects
SAN MATEO, Calif., March 30, 2022 The Gastric Cancer Foundation (GCF) has announced the launch of its 2022 grant program.... Read More
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Partner with a Navigator to Find the Right Clinical Trial
More than 750 clinical trials of potential new treatments for gastric cancer are now enrolling patients or are planning to... Read More
Foundation Grant Recipients Report Progress in Studies in Epigenetics and Chromosomal Instability
Last year, the Gastric Cancer Foundation awarded two $75,000 grants to researchers probing new targets for treating gastric cancer. Now... Read More
Gastric Cancer Registry Makes Strides Towards Major Data Expansion
Earlier this year, the Gastric Cancer Foundation committed $257,856 to the Gastric Cancer Registry at Stanford University, which is using... Read More
Foundation Research Scholar Reports Progress in Project Focused on Peritoneal Spread
When Samuel J. Klempner, M.D. received the $300,000 Ben Feinstein Memorial Research Scholar Award from the Gastric Cancer Foundation and... Read More
Foundation Awards New Grants to Researchers Pursuing Novel Approaches in Gastric Cancer
The biggest challenge facing researchers who have exciting but unproven ideas for fighting gastric cancer is raising the funds they... Read More
Nivolumab/Paclitaxel Combo Shows Antitumor Activity in EBV-Related, MSI-H, PD-L1+ Advanced Gastric Cancer
Opdivo combined with paclitaxel showed anti-tumor activity in a phase 1/2 study of gastric cancer patients with a variety of... Read MoreGastric Cancer Registry Team Reports Major Progress in Webinar
In April, Hanlee Ji, MD, associate professor of medicine at Stanford University and principal investigator of the Gastric Cancer Registry,... Read More
Amgen’s Investigational Bemarituzumab Receives Breakthrough Therapy Designation
The FDA granted breakthrough therapy designation to an experimental drug from Amgen for patients with FGFR2b over expressing and HER2-negative... Read More
Investigational Anti-PD-1 Agent Shows Potential for Treatment of Unresectable or Metastatic MSI-H/dMMR Solid Tumors
The novel checkpoint inhibitor HLX10 showed positive safety and efficacy in a phase 2 clinical trial in patients with microsatellite... Read More
Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
A study found that patients with gastroesophageal junction cancer who were treated with surgery and chemoradiotherapy had significantly longer disease-free... Read More
FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
The FDA approved the first immunotherapy for the first-line treatment of advanced gastric cancer, Bristol Myers Squibb’s Opdivo in combination... Read More
Heavy Alcohol Use Is Associated With Gastric Cancer
A study in the American Journal of Gastroenterology found an association between heavy alcohol use and an increased risk of... Read More-
Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy
A recent study found that patients over 70 with esophageal cancers benefited from “triple modality” surgery that included surgery, with... Read More 
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Merck received FDA approval for Keytruda plus chemotherapy for some patients with advanced esophageal or gastroesophageal junction cancer.
Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer
Ambrx was granted orphan drug designation by the FDA for its drug ARX788, which is in clinical trials to treat... Read More
Zolbetuximab Plus EOX vs EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma
In a phase 2 trial in advanced gastric cancer with high expression of CLDN18.2, adding Ganymed Pharmaceuticals’experimental drug zolbetuximab to... Read More
Safety and feasibility of minimally invasive surgical interventions for esophageal and gastric cancer in the acute setting
Dutch researchers found in a recent study that minimally invasive surgery in gastric cancer is safe, feasible and offers comparable... Read More
New Published Research from the Gastric Cancer Registry Team
Our Gastric Cancer Registry project at Stanford is leading to important research and new discoveries. A recently published study used... Read More
Quality of Life Maintained With Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
A study presented at ASCO GI found that the immunotherapy drug Opdivo given to gastric cancer patients after surgery lowers... Read More
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.